AKT1 and prostate carcinoma: To understand the functional impact of PI3K/AKT and ERK1/2 signaling pathways in prostate cancer cells, two pharmacological inhibitors, LY294002 and U0126 were used to block PI3K/AKT and ERK1/2 signaling pathway respectively (Fig. 4A–B and S6A–B Figure).